News

Kymriah will be assessed under a priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with DLBCL who are ineligible for

Sandoz biopharmaceuticals development global head Mark Levick said: "When patients are dealing with a chronic disease, it is imperative they have access to important medication that will help

Adynovi is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding. It

Both OS and PFS were defined to be the dual primary endpoints of the pivotal late-stage trial dubbed KEYNOTE-189. The trial assessed the combination of Keytruda, Lilly’s pemetrexed

DIPG disease is mostly observed in young children with a median survival of nine months. Midatech Pharma said the approval of MTX110 trial is a big step towards development

Developed by Grünenthal, Tramal is a well-established analgesic for the treatment of moderate to severe pain. It is the only international brand of tramadol in China that includes sustained

Intellegens and Biorelate have AI tools, which can enhance e-Therapeutics’ existing computational network-driven drug discovery (NDD) technology. Intellegens is a spin-out from the University of Cambridge, which has developed an

Following this study the two companies have agreed the terms of a licensing deal which will allow them to develop drug conjugates using the combined technologies.  The detailed

Telix Japan is wholly-owned operating subsidiary of Telix Pharmaceuticals Limited. The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to